BCG vaccine of 2004 the vaccine is given to about 100 million children per year globally. The main use of BCG is for vaccination against tuberculosis. BCG vaccine can be administered after birth intradermally. BCG vaccination can cause a false positive Mantoux test, although a very high-grade reading is usually due to active disease. The most controversial aspect of BCG is the variable efficacy found in different clinical trials, which appears to depend on geography. Trials conducted in the UK have consistently shown a protective effect of 60 to 80%, but those conducted elsewhere have shown no protective effect, and efficacy appears
Inoculation theory to back that idea up. There are also scholars on the other side who suggest that too much of a delay lessens the strengthening effect of inoculation. With this being said, it has been revealed that the effect of inoculation can still be significant weeks or even months after initial introduction or the treatment showing that it does produce somewhat long-lasting effects (Banas & Rains, 2010). Involvement is the final element of the inoculation process. Pfau, et al. (1997a) defined involvement as "the importance or salience of an attitude object for a receiver" and is “among the most important and